Skip to Content

Join the 'Chronic Myelogenous Leukemia (CML)' group to help and get support from people like you.

Chronic Myelogenous Leukemia (CML) News

Related terms: Cancer, Chronic Myelogenous Leukemia, Chronic Granulocytic Leukemia, Leukemia, Chronic Granulocytic, CML

Generic Drugs Don't Always Push Prices Down

Posted 7 May 2018 by Drugs.com

MONDAY, May 7, 2018 – Generic drugs tend to trigger big drops in the cost of their expensive, brand-name counterparts, but that has not been the case with the cancer drug commonly known as Gleevec (imatinib). There's been only a small drop in the price of imatinib since a generic version was introduced to compete with Gleevec, a new study finds. Gleevec is used to treat chronic myeloid leukemia. ...

Novartis Drug Tasigna Approved by FDA to Treat Children with Rare Form of Leukemia

Posted 8 Apr 2018 by Drugs.com

Basel, March 22, 2018 - Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). In the United States, Tasigna is now indicated for the treatment ...

FDA Approves Pfizer’s Bosulif (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)

Posted 9 Jan 2018 by Drugs.com

December 19, 2017 – Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for Bosulif (bosutinib) to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). The sNDA was reviewed and approved under the FDA’s Priority R ...

FDA Updates the Label of Tasigna to Reflect that Certain Patients with a Type of Leukemia May be Eligible to Stop Treatment After Sustained Response

Posted 30 Dec 2017 by Drugs.com

December 22, 2017 – The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotinib) to include information for providers about how to discontinue the drug in certain patients. Tasigna, first approved by the FDA in 2007, is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). With today’s u ...

FDA Expands Approval of Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Posted 16 Nov 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) November 10, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel (dasatinib) tablets to include the treatment of children with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP).1 This approval for Sprycel in pediatric patients ...

Can Drug Company Perks Sway Cancer Docs' Prescriptions?

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Cancer doctors who receive freebies from pharmaceutical companies are more likely to prescribe drugs produced by those companies, a new study reports. Free meals, paid travel expenses and fees for consulting or lecturing appeared to influence which drugs a doctor would choose when treating two different types of cancer, said study lead researcher Dr. Aaron Mitchell. ...

Cancer Drug, Dasatinib, Helps Some Kids With Rare Type of Leukemia

Posted 5 Jun 2017 by Drugs.com

MONDAY, June 5, 2017 – The cancer drug dasatinib shows promise in treating children with chronic myeloid leukemia (CML) caused by the gene BCR-ABL, also known as the Philadelphia chromosome, researchers report. "Despite the fact that there is a common molecular driver – BCR-ABL – for this disease in adults and in children, the manifestation in children is different. Pediatric patients tend to ...

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study

Posted 9 Mar 2017 by Drugs.com

WEDNESDAY, March 8, 2017 – The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment – with no signs of additional safety risks, a new study finds. Gleevec – known generically as imatinib – was hailed as a "wonder drug" when it was introduced in 2001 for treating chronic myeloid leukemia (CML). CML is a type of blood cancer that strikes about 5,000 ...

Generic Gleevec Will Likely Cut Millions in Health Costs

Posted 19 Mar 2016 by Drugs.com

FRIDAY, March 18, 2016 – Using the generic form of the cancer drug Gleevec could save patients and insurers millions of dollars, a new study suggests. The patent on Gleevec expired in January. The generic version of the drug is called imatinib. The drug is used to treat chronic myeloid leukemia. Most people with chronic myeloid leukemia require lifelong daily medication, researchers said. "If we ...

New Immune Therapy Achieves Complete Remission in Blood Cancer Patients

Posted 16 Feb 2016 by Drugs.com

A new therapy that uses a person's immune system to attack tumors led to complete remission in terminally ill blood cancer patients, according to researchers. In a clinical trial, symptoms vanished in 94 percent of leukemia patients who received the treatment. The response rate was more than 80 percent in patients with other blood cancers, and half achieved total remission, CNBC reported. The ...

Antibody May Lower Rejection Rates After Stem Cell Transplant in Leukemia Patients

Posted 7 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 6, 2016 – People with acute leukemia who were given antibody therapy before a stem cell transplant fared better than those who didn't receive the treatment, a small study found. Stem cell transplantation allows doctors to give higher doses of cancer-killing chemotherapy, according to the American Cancer Society. However, the odds of the body rejecting the transplanted stem cells ...

End-of-Life Talk Often Comes Too Late for Blood Cancer Patients

Posted 21 Dec 2015 by Drugs.com

MONDAY, Dec. 21, 2015 – Many doctors wait too long to have end-of-life discussions with blood cancer patients, a new study finds. Researchers analyzed surveys completed by 349 blood cancer specialists, and found that 56 percent said end-of-life discussions with patients happen too late. Nearly 43 percent said they had their first end-of-life discussions with patients at less-than-ideal times, ...

Sun Pharma Announces FDA Approval for Generic Gleevec

Posted 6 Dec 2015 by Drugs.com

Mumbai, December 04, 2015: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharma) today announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec, Imatinib Mesylate tablets 100mg and 400mg. Imatinib Mesylate tablets, 100 mg and 400 mg are ...

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is ...

Could Common Diabetes Drugs Help Fight Leukemia?

Posted 2 Sep 2015 by Drugs.com

WEDNESDAY, Sept. 2, 2015 – Common diabetes drugs might help eradicate drug-resistant cancer cells in a certain form of leukemia when added to standard treatment, a small new study suggests. Researchers found that patients with chronic myeloid leukemia (CML) who received a glitazone – a class of drug for type 2 diabetes – along with the standard CML drug imatinib remained disease-free for up to ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Leukemia

Related Drug Support Groups

Gleevec, hydroxyurea, Sprycel, Tasigna, Hydrea, anagrelide, nilotinib, imatinib, Agrylin, view more... cyclophosphamide, cytarabine, Bosulif, Synribo, Myleran, omacetaxine, Busulfex, ponatinib, busulfan, bosutinib, peginterferon alfa-2b, interferon alfa-2a, fludarabine, dasatinib, Iclusig